Link to Full Article Global Powered Exoskeleton Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 contains an extremely knowledgeable and in-depth evaluation of the present industrial conditions along with market size, estimated from 2020 to 2025. The report encompasses several factors such as global manufacturers, market size, and market factors that affect global […]
Link to Full Article MoneyTalks is Stockhead’s regular recap of the ASX stocks and sectors that fund managers and analysts are looking at right now. Today we hear from BioScience Managers’ managing partner Dr Graham Crooke. BioScience Managers is an Australian life sciences investor established in 2003 and has a solid investment record making over 200 investments across […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-02-11 22:54:582021-02-11 22:54:58BIOSCIENCE MANAGERS: This biotech focused fund explains why it invested $15m in these 2 ASX stocks
Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma Announces Brazilian Patent Granted for XF-73 nasal gel preventing post-surgical infections Brighton, United Kingdom – 3rd February 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening […]
Link to Full Article Agreement with Gabriel Precision Oncology to support the routine use of advanced cancer genomics in healthcare Cambridge, United Kingdom – 03 February 2021 – Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, announces a collaboration with Gabriel Precision Oncology Limited (“Gabriel”), a spin-out […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-02-03 02:03:322021-02-04 02:05:15Congenica Enters Cancer Collaboration with University of Glasgow Spinout Gabriel Precision Oncology
Link to Full Article Acrux (ACR) has wrapped up a share purchase plan that was more than seven times oversubscribed after receiving approximately $15.1 million in applications The placement has since been scaled back to roughly $9.9 million, but still marks a significant increase on the $2 million it was initially seeking ACR says funds […]
Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma plc strengthens its Scientific Advisory Board with the appointment of Professor Mark Wilcox A recognised leader in UK/NHS infection prevention and control, and a renowned expert in C. difficile infection Brighton, United Kingdom – 2 February 2021 – Destiny Pharma Plc (AIM: […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-02-02 02:07:032021-02-04 02:08:11Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board
D-dimer levels have been correlated with disease severity and risk of mortality in patients with COVID-19 Treatment with Auxora improved D-dimer levels in patients with severe COVID-19 pneumonia LA JOLLA, Calif., February 2, 2021 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-02-02 01:57:462021-02-04 01:58:30CalciMedica Presents New Clinical Data Demonstrating Improved D-Dimer Biomarker Levels with Auxora™ in Severe COVID-19 Pneumonia at the 50th Critical Care Congress
Link to Full Article MARINA DEL REY, Calif., Jan. 27, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement to sell Armata common stock and warrant securities to Innoviva […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-01-27 01:55:352021-02-04 01:56:37Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company’s Bacteriophage Development Programs
Link to Full Article Artarmon, Australia – January 20, 2021 – Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of closed-loop spinal cord stimulation for the treatment of chronic pain, announced scientific highlights from the 2021 North American Neuromodulation Society (NANS 2021) Virtual Meeting, including real-world European commercial results and sub-analyses of 24-month […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-01-20 02:20:362021-02-04 02:21:31Saluda Medical Announces Highlights from 2021 North American Neuromodulation Society (NANS) Meeting
Link to Full Article Cambridge, United Kingdom – 14 January 2021 – Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces the launch of a Patient Advocacy and Engagement Advisory Board. Working with the Congenica Board of Directors and wider senior leadership team, this group […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-01-14 02:01:552021-02-04 02:03:17Leading advocacy professionals to ensure patient remains central to Congenica’s approach
REX BIONICS – Global Powered Exoskeleton Market 2020 Latest Trends
/in Rex BionicsLink to Full Article Global Powered Exoskeleton Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 contains an extremely knowledgeable and in-depth evaluation of the present industrial conditions along with market size, estimated from 2020 to 2025. The report encompasses several factors such as global manufacturers, market size, and market factors that affect global […]
BIOSCIENCE MANAGERS: This biotech focused fund explains why it invested $15m in these 2 ASX stocks
/in Acrux, BioSciences Managers, CynataLink to Full Article MoneyTalks is Stockhead’s regular recap of the ASX stocks and sectors that fund managers and analysts are looking at right now. Today we hear from BioScience Managers’ managing partner Dr Graham Crooke. BioScience Managers is an Australian life sciences investor established in 2003 and has a solid investment record making over 200 investments across […]
Destiny Pharma announces Brazilian Patent granted for XF-73 nasal gel
/in Destiny PharmaLink to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma Announces Brazilian Patent Granted for XF-73 nasal gel preventing post-surgical infections Brighton, United Kingdom – 3rd February 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening […]
Congenica Enters Cancer Collaboration with University of Glasgow Spinout Gabriel Precision Oncology
/in CongenicaLink to Full Article Agreement with Gabriel Precision Oncology to support the routine use of advanced cancer genomics in healthcare Cambridge, United Kingdom – 03 February 2021 – Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, announces a collaboration with Gabriel Precision Oncology Limited (“Gabriel”), a spin-out […]
Acrux (ASX:ACR) receives $15M in applications for $2M SPP
/in AcruxLink to Full Article Acrux (ACR) has wrapped up a share purchase plan that was more than seven times oversubscribed after receiving approximately $15.1 million in applications The placement has since been scaled back to roughly $9.9 million, but still marks a significant increase on the $2 million it was initially seeking ACR says funds […]
Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board
/in Destiny PharmaLink to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma plc strengthens its Scientific Advisory Board with the appointment of Professor Mark Wilcox A recognised leader in UK/NHS infection prevention and control, and a renowned expert in C. difficile infection Brighton, United Kingdom – 2 February 2021 – Destiny Pharma Plc (AIM: […]
CalciMedica Presents New Clinical Data Demonstrating Improved D-Dimer Biomarker Levels with Auxora™ in Severe COVID-19 Pneumonia at the 50th Critical Care Congress
/in CalcimedicaD-dimer levels have been correlated with disease severity and risk of mortality in patients with COVID-19 Treatment with Auxora improved D-dimer levels in patients with severe COVID-19 pneumonia LA JOLLA, Calif., February 2, 2021 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe […]
Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company’s Bacteriophage Development Programs
/in Armata PharmaceuticalsLink to Full Article MARINA DEL REY, Calif., Jan. 27, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement to sell Armata common stock and warrant securities to Innoviva […]
Saluda Medical Announces Highlights from 2021 North American Neuromodulation Society (NANS) Meeting
/in Saluda MedicalLink to Full Article Artarmon, Australia – January 20, 2021 – Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of closed-loop spinal cord stimulation for the treatment of chronic pain, announced scientific highlights from the 2021 North American Neuromodulation Society (NANS 2021) Virtual Meeting, including real-world European commercial results and sub-analyses of 24-month […]
Leading advocacy professionals to ensure patient remains central to Congenica’s approach
/in CongenicaLink to Full Article Cambridge, United Kingdom – 14 January 2021 – Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces the launch of a Patient Advocacy and Engagement Advisory Board. Working with the Congenica Board of Directors and wider senior leadership team, this group […]